SLU-PP-332

By initiating exercise-like adaptations at the cellular level, SLU-PP-332 has become a compound of interest in metabolic research related to obesity, insulin resistance, cardiometabolic dysfunction, and reduced physical capacity. Preclinical studies indicate that ERR activation by SLU-PP-332 promotes oxidative metabolism in skeletal muscle, increases overall energy expenditure, and supports more efficient fuel utilization across multiple tissues (Zuercher et al., 2023 — Journal of Medicinal Chemistry).

(Liu et al., 2024 — Nature Chemical Biology).

Beyond systemic metabolism, SLU-PP-332 has demonstrated effects on cardiac energy homeostasis. In experimental models of cardiac dysfunction, ERR stimulation improves mitochondrial performance, supports myocardial energy balance, and attenuates fibrotic remodeling. These findings position SLU-PP-332 as a valuable research tool for studying exercise mimetics, metabolic disease pathways, and cardiometabolic resilience (Dufour et al., 2023 — Cell Reports).

SLU-PP-332 is supplied as a research-grade compound verified for purity prior to dispatch. Its small-molecule format ensures compatibility with standard in vitro assay conditions and facilitates precise dosing in experimental protocols. Researchers investigating mitochondrial biogenesis, exercise adaptation mechanisms, or metabolic resilience may find this compound particularly suitable for controlled model systems requiring selective ERR pathway engagement without off-target receptor activity.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.